Celltrion to seek new drug, CDMO partners at int'l pharmaceutical exhibition in Milan
Summary
Celltrion said Tuesday it will use the CPHI Worldwide trade show in Milan next month to seek partners in new drug development, contract manufacturing and supply chains. The company plans to target oncology, obesity and metabolic diseases, and autoimmune diseases as its new drug research begins to show results. It also wants to expand overseas raw material and contract manufacturing partnerships, and to pursue CDMO deals as global demand rises.
Key Facts
- CPHI Worldwide will run Oct. 6-8 in Milan, and more than 60,000 industry professionals from about 2,400 companies in some 170 countries are expected to attend.
- Celltrion said it is best known for biosimilars, which are lower-cost versions of biologic drugs whose patents have expired.
- The company said this year marks the fifth straight year since 2022 that it has set up its own booth at the event.
- Celltrion said this year’s booth covers about 152 square meters and includes a dedicated meeting room and a separate lounge for back-to-back business meetings.
- A Celltrion official said the show will be used to showcase the company’s drug development and manufacturing competitiveness and to further solidify a stable global supply chain.
An image of Celltrion's booth during the CPHI Worldwide Milan / Courtesy of Celltrion
Celltrion will use one of the world's largest pharmaceutical trade shows next month to seek partners in new drug development, contract manufacturing and supply chains, the Korean biopharmaceutical company said Tuesday.
The company will take part in CPHI Worldwide, which runs Oct. 6-8 in Milan. Now in its 37th year, the event covers pharmaceutical manufacturing, supply chains and contract development and manufacturing. More than 60,000 industry professionals from about 2,400 companies in some 170 countries are expected to attend.
Celltrion, best known for biosimilars — lower-cost versions of biologic drugs whose patents have expired — said it will look for partners in oncology, obesity and metabolic diseases, and autoimmune diseases. The company said its new drug research in these areas has recently begun producing results. It described the effort as part of its push to become a global developer of new drugs.
As demand for its main products grows, the company also plans to strengthen existing partnerships with overseas raw material suppliers and contract manufacturers. It will look for new partners to diversify its supply chain and lower costs.
Celltrion also plans to pursue partnerships in contract development and manufacturing, known as CDMO, as global demand rises. In this business, a company develops and produces drugs for other pharmaceutical firms. Celltrion said it will offer partners its experience in developing antibody drugs and its production capacity.
It is the fifth straight year since 2022 that the company has set up its own booth at the show. This year's booth covers about 152 square meters and includes a dedicated meeting room and a separate lounge for back-to-back business meetings.
"This CPHI will be an opportunity to showcase Celltrion's drug development and manufacturing competitiveness on the global stage and further solidify a stable global supply chain," a Celltrion official said.
This article was published with the assistance of generative AI and edited by The Korea Times.
Explore More
- Q.
- Q.
- Q.